What to expect in the Ultragenyx Pharmaceutical Inc. interview process

Based on publicly available sources, Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biotechnology research company headquartered in Novato, California, focused on developing treatments for rare and ultra-rare diseases. Founded in 2010, the company operates globally across 8 countries and maintains a workforce distributed across 20 countries.

Public data indicates that the company has experienced a contraction in its workforce. Headcount data shows a decline from 1,429 employees in 2023 to approximately 1,320 employees by March 2026, alongside a reported 10% workforce reduction announced in February 2026. Hiring activity has also slowed significantly; active job postings dropped by 128.1% to 16 open roles in 2026 compared to the previous year.

From a financial and operational perspective, Ultragenyx remains an unprofitable enterprise that funnels a substantial portion of its resources into research and development—directing approximately 62% of its operating expenses into R&D in 2025. The company's portfolio features commercialized FDA-approved drugs, such as burosumab for Tumor Induced Osteomalacia and UX007 for Long-chain Fatty Acid Oxidation Disorders, alongside a broad clinical pipeline. Regarding employment-based immigration, data shows active filings for H-1B visas and green cards, though overall petition volumes remain modest.